KOSPI maintains a normal array, while KOSDAQ is in a reverse array, with individual biotech companies' specific schedules identified as short-term volatility factors.
Want the next one from this channel too?
Despite Moderna's significant positive news, the domestic biotech sector generally showed a sluggish performance. The KOSDAQ Bio 150 index surged over 8% at one point during the day but then gave back its gains, causing disappointment. Even leading bio stocks such as Alteogen and ST Pharm failed to meet market expectations, indicating that current investor sentiment towards biotech is not positive.
Manager Shin Kwang-sup emphasized investing primarily in stocks with a normal array in the current market. While KOSPI maintains a normal array, KOSDAQ is in a reverse array. He advised focusing on stable normal array stocks rather than chasing short-term spikes in reverse array stocks.
The current KOSDAQ margin loan balance is 6.4 trillion won, and Manager Shin Kwang-sup analyzed that anything below 8 trillion won can be considered an 'empty house' state. For the market to become active, the margin loan balance needs to increase to at least 7 trillion won. The current lack of liquidity is identified as a major factor limiting the market's buying power. This 'empty house' situation makes it difficult to predict short-term movements in the KOSDAQ market.
Manager Shin Kwang-sup predicted that KOSPI would rise to the mid-8,000s in the short term, followed by a period of adjustment. There is also a possibility that KOSPI could reach historical highs in the first quarter of next year. For KOSDAQ, he analyzed that an increase in margin loans is essential to break the 900-point mark. At the current margin loan level, there are limits to index growth, suggesting the need for additional liquidity inflow. These index forecasts are expected to be an important basis for investment strategy formulation.
At most, it will go up to the mid-8s. It will come up to about here. Yes. Within a month or two. But it will fall from here and go into a period of adjustment.
ABL Bio plans to release clinical data for its ABL-503 compound at a conference in Madrid, Spain, in late October. ABL-503 is currently in Phase 2 clinical trials, and the patient cohort has been expanded. Attention is focused on how this data release will affect ABL Bio's stock price.
HLB has an important schedule related to its liver cancer treatment on September 27th. A competitor's liver cancer treatment is expected to receive FDA approval, and analysis suggests that if the competitor is approved, it could cause a short-term shock to HLB's stock price. Additionally, HLB is scheduled to release abstract data at the ESMO conference in October, which is also garnering market attention.
Olix is scheduled to announce its hair loss treatment clinical data results next week. The current market sentiment is focused on obesity, oncology, and vaccine fields, so interest in hair loss treatments is relatively low. However, attention is on whether these data results could be a catalyst for a rebound in Olix's stock price. Investors are expected to closely monitor the data content and market reaction.
Regarding market speculation about a final contract for Peptron on September 7th, Manager Shin Kwang-sup stated that investors should wait until October. The primary reason for Peptron's recent stock price increase is analyzed to be the news of its second plant expansion currently under construction in Osong, Cheongju. Manager Shin recommended a strategy of selling if the stock price surges before a final contract is signed, and buying if it consolidates. This calls for a cautious approach from investors.
D&D Pharmatech was identified as a stock that could rise most sharply if a supply-demand short squeeze occurs. However, there has been no confirmed news regarding a license-out agreement for its key compound, DD01, and currently, only expectations exist. Manager Shin Kwang-sup predicted it could surpass 100,000 won this year but warned that the stock's volatility would be high. Investors should focus on official announcements and approach cautiously. It is pointed out that relying solely on expectations for investment carries significant uncertainty.
Answers come from the transcript, with the exact spot cited.
Want the next one from this channel too?
When MBN골드 publishes, we'll write it up like the one you just read and email it to you.
{channel} published 93 in the last 7 days.
We skip Shorts. You can unfollow any time.
